Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a randomized controlled trial

JA Halliday; S Russell-Green; B Lam; S Trawley; SA McAuley; LA Bach; MG Burt; ND Cohen; PG Colman; EA Davis; DJ Holmes-Walker; AJ Jenkins; J Kaye; AC Keech; MH Lee; RW Mccallum; B Paldus; SN Stranks; V Sundararajan; G Ward; TW Jones; D O'neal; J Speight; C Hendrieckx; SA Mcauley; MH Lee; B Paldus; CM Sims; RJ Macisaac; GM Ward; PG Colman; ND Cohen; LA Bach; K Kumareswaran; SN Stranks; MG Burt; RW Mccallum; J Kaye; J Speight; C Hendrieckx; JA Halliday; AJ Jenkins; A Januszewski; AC Keech; S Vogrin; V Sundararajan; HM Husin; PM Clarke; TW Jones; EA Davis; MID Bock; MB Abraham; GR Ambler; FJ Cameron; JM Fairchild; BR King

Journal article

Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a randomized controlled trial

JA Halliday, S Russell-Green, B Lam, S Trawley, SA McAuley, LA Bach, MG Burt, ND Cohen, PG Colman, EA Davis, DJ Holmes-Walker, AJ Jenkins, J Kaye, AC Keech, MH Lee, RW Mccallum, B Paldus, SN Stranks, V Sundararajan, G Ward Show all

BMJ Open Diabetes Research & Care | BMJ Publishing Group | Published : 2024

DOI: 10.1136/bmjdrc-2024-004428

Download PDF

Abstract

Introduction This analysis aimed to investigate diabetes-specific psychological outcomes among adults with type 1 diabetes (T1D) using hybrid closed-loop (HCL) versus standard therapy. Research design and methods In this multicenter, open-label, randomized, controlled, parallel-group clinical trial, adults with T1D were allocated to 26 weeks of HCL (MiniMed™ 670G) or standard therapy (insulin pump or multiple daily injections without real-time continuous glucose monitoring). Psychological outcomes (awareness and fear of hypoglycemia; and diabetes-specific positive well-being, diabetes distress, diabetes treatment satisfaction, and diabetes-specific quality of life (QoL)) were measured at enr..

View full abstract

University of Melbourne Researchers

Steven Trawley Author

Sybil McAuley Author

Peter Colman Author

Alicia Jenkins Author

Related Projects (1)

Advancement of automated insulin delivery for adults with type 1 diabetes

Grants

Awarded by Australian Research Council

Funding Acknowledgements

The trial was funded by JDRF Australian Type 1 Diabetes Clinical Research Network (3- SRA- 2016- 351- M- B), a special initiative of the Australian Research Council, and the National Health and Medical Research Council of Australia (APP1099379). In- kind support was provided by Medtronic (HCL systems, masked CGM devices, and technical expertise with device issues) and Roche Diabetes Care (blood glucose meters for participants using MDI). Additionally, JAH and SR- G are supported by an unrestricted educational grant provided to the Australian Centre for Behavioural Research in Diabetes (ACBRD) by Diabetes Australia. JS and CH are supported by core funding to the ACBRD provided by the collaboration between Diabetes Victoria and Deakin University. SAM is supported by a Breakthrough T1D (formerly JDRF) Research Award (5- ECR- 2017- 371- A- N). BP is supported by a University of Melbourne Scholarship and research support from JDRF. AJJ is supported by a National Health and Medical Research Council Fellowship and is a Sydney Medical School Foundation Fellow. AJJ received research support from the National Health and Medical Research Council of Australia, JDRF Australia, and JDRF International. JDRF Australia provided input into the overall trial design. The funders had no role in data collection, data analysis, data interpretation, or writing of this manuscript.